Richard Branson takes 23andMe public with his SPAC, as the GlaxoSmithKline partner aims to beef up drug R&D
One of the buzziest names in healthcare and delivering personalized medicine directly based on a customer’s genetics went public Thursday, and used a high-profile billionaire’s SPAC to do it.
23andMe pulled off a reverse merger with Richard Branson’s VG Acquisition Corp, the company announced Thursday morning. The deal will deliver $759 million in funding via $509 million in cash and a $250 private placement, and values the company at $3.5 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.